Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: A novel mechanism of anti- inflammatory activity

Biochemical Pharmacology

Volumn 53, Issue 12, 1997, Pages 1901-1907

  Pruzanski, Waldemar ^a,c   Stefanski, Eva ^a   Vadas, Peter ^a   Ramamurthy, Nungavaram S ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b STONY BROOK UNIVERSITY   (United States)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Inflammation; Phospholipase A2; Sulfasalazine

Indexed keywords

ANTIINFLAMMATORY AGENT; BUCLADESINE; FORSKOLIN; LIPOPOLYSACCHARIDE; MESALAZINE; PHOSPHOLIPASE A2; RECOMBINANT INTERLEUKIN 1BETA; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; SALAZOSULFAPYRIDINE; SULFAPYRIDINE;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CROHN DISEASE; DISEASE ACTIVITY; DRUG EFFECT; ENZYME ASSAY; ENZYME INHIBITION; FETUS; INFLAMMATION; INFLAMMATORY DISEASE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN SYNTHESIS; RAT; RHEUMATOID ARTHRITIS;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; BENZOPHENONES; CELLS, CULTURED; DINOPROSTONE; GELATINASES; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-1; LIPOPOLYSACCHARIDES; PHOSPHOLIPASES A; SULFASALAZINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030786363     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00137-8     Document Type: Article

References (39)

1. Hannonen P, Mottonen T, Hakola M and Oka M, Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 36: 1501-1509, 1993.
2. Wilkieson CA, Madhok R, Hunter JA and Capell HA, Toleration, side-effects and efficacy of sulphasalazine in rheumatoid arthritis patients of different ages. Q J Med 86: 501-505, 1993.
3. Smedegard G and Bjork J, Sulphasalazine: Mechanism of action in rheumatoid arthritis. Br J Rheumatol 2(Suppl 34): 7-15, 1995.
4. Capell HA, Clinical efficacy of sulphasalazine - A review. Br J Rheumatol 2: 35-39, 1995.
5. van Riel PL, van Gestel AM and van de Putte LB, Long-term usage and side-effect profile of sulphasalazine in rheumatoid arthritis. Br J Rheumatol 2: 40-42, 1995.
6. Dougados M, vam der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, Zeidler H, Kvien TK, Olivieri I and Dijkmans B, Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 38: 618-627, 1995.
7. Selby W, Current management of inflammatory bowel disease. J Gastroenterol Hepatol 8: 70-83, 1993.
8. Kornbluth AA, Salomon P, Sacks HS, Mitty R and Janowitz HD, Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis. J Clin Gastroenterol 16: 215-218, 1993.
9. Carlin G, Djursater R and Smedegard G, Sulphasalazine inhibition of human granulocyte activation by inhibition of second messenger compounds. Ann Rheum Dis 51: 1230-1236, 1992.
10. Tornhamre S, Edenius C, Smedegard G, Sjoquist B and Lindgren JA, Effects of sulfasalazine and sulfasalazine analogue on the formation of lipoxygenase and cyclooxygenase products. Eur J Pharmacol 169: 225-234, 1989.
11. Carlin G, Nyman A-K and Gronberg A, Effects of sulfasalazine on cytokine production by mitogen-stimulated human T-cells. Arthritis Rheum 37: S383, 1994.
12. Gronberg A, Isaksson P and Smedegard G, Inhibitory effect of sulfasalazine on production of IL-1β, IL-6 and TNF-β. Arthritis Rheum 37: S383, 1994.
13. Carlin G, Sulfasalazine does not inhibit cyclooxygenases 1 and 2. Arthritis Rheum 37: S383, 1994.
14. 2 secretion is a common effector pathway of interleukin-1 and tumor necrosis factor. Immunol Lett 28: 187-194, 1991.
15. 2 from synovial fluid in rheumatoid arthritis. J Biochem (Tokyo) 100: 1297-1303, 1986.
16. Zucker S, Lysik RM, Ramamurthy NS, Golub LM, Wieman JM and Wilkie DP, Diversity of plasma membrane proteinases in mouse melanoma cells: Inhibition of collagenolytic and cytolytic activity by minocycline. J Natl Cancer Inst 75: 517-525, 1985.
17. Chang K-M, Ryan ME, Golub LM, Ramamurthy NS and McNamara TF, Local and systemic factors in periodontal disease increase matrix-degrading enzyme activities in rat gingiva: Effect of micocycline therapy. Res Commun Mol Pathol Pharmacol 91: 303-318, 1996.
18. Tso JY, Sun XH, Kao TH, Reece KS and Wu R, Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs. Genomic complexity and molecular evolution of the gene. Nucleic Acids Res 13: 2485-2502, 1985.
19. Danis VA, Franic GM, Rathjen DA, Laurent RM and Brooks PM, Circulating cytokine levels in patients with rheumatoid arthritis: Results of a double blind trial with sulfasalazine. Ann Rheum Dis 51: 946-950, 1992.
20. 2 expression and inflammation: The relationship with associated disease states. J Lipid Mediat 8: 1-30, 1993.
21. 2. In: Novel Molecular Approaches to Anti-Inflammatory Therapy (Agents and Actions Suppl 46) (Eds. Pruzanski W and Vadas P), pp. 65-76. Birkhauser Verlag, Basel, 1995.
22. 2 in inflammatory synovial fluids. Inflammation 16: 437-443, 1992.
23. 2 as an index of disease activity in rheumatoid arthritis. Prospective double-blind study of 212 patients. J Rheumatol 23: 1162-1166, 1996.
24. 2 levels with circulatory collapse. Crit Care Med 16: 1-7, 1988.
25. 2 expression in adults with malaria. Infect Immun 60: 3928-3931, 1992.
26. 2 with multisystem organ failure due to salicylate intoxication. Crit Care Med 21: 1087-1091, 1993.
27. 2. Am J Pathol 134: 807-811, 1989.
28. 2 induces an inflammatory response in rabbit joints. J Immunol 146: 3904-3910, 1991.
29. 2 induces a synovitis-like inflammation in the rat air pouch. J Rheumatol 21: 824-829, 1994.
30. 2 in rabbits. J Invest Dermatol 86: 380-383, 1986.
31. 2 from human ileal mucosa. Biochim Biophys Acta 1170: 125-130, 1993.
32. 2 immunochemically related to group II enzyme in inflammatory bowel disease: Its correlation with disease activity of Crohn's disease and ulcerative colitis. Gut 33: 914-921, 1992.
33. 2 activity. Scand J Gastroenterol 27: 691-694, 1992.
34. 2 protein in sera of patients with Crohn's disease and ulcerative colitis. Am J Gastroenterol 88: 1076-1080, 1993.
35. 2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis. Gut 35: 1593-1598, 1994.
36. 2 gene expression and activity in histologically normal ileal mucosa and in Crohn's ileitis. Gut 37: 380-385, 1995.
37. 2 in rat mesangial cells. Biochem Biophys Res Commun 174: 268-275, 1991.
38. 2 expression and arachidonic acid release by rabbit articular chondrocytes. FEBS Lett 340: 51-55, 1994.
39. 2 cells, rat astrocytes and rabbit articular chrondrocytes. In: Esterases, Lipases and Phospholipases (Eds. Mackness MI and Clerc M), pp. 213-222. Plenum Press, New York, 1994.